HepQuant is a privately-held, early-stage medical diagnostics company with unique, patented and patent-pending technology for assessing liver function of patients with chronic liver disease. HepQuant technologies, licensed from the University of Colorado Denver (UCD), have been advanced with the intent to profoundly impact the liver disease landscape – including the research, treatment and patient communities – with diagnostic products that are accurate and minimally invasive.
HepQuant will be attending / presenting at the following local, national or international meetings:
Liver / PSC Forum | Washington, DC | January 29-31, 2021
2021 AASLD/FDA DILI Conference Drug Induced Liver Injury | Virtual Conference | April 20 – 22, 2021 | “New Developments, Innovative Tools and Assessment Strategies in Patients with Underlying Liver Disease or Cancer and in the Setting of the Covid-19 Pandemic” | Gregory T. Everson, MD, FAASLD Presenting “Non-invasive Quantitative Liver Tests for Disease Activity and Fibrosis: Can They Reliably Guide Optimal Treatment Regimens During the Progression of CLD” on Tuesday, April 20, 2021 11:30 a.m. to 11:50 a.m.
AASLD: The Liver Meeting Digital Experience | November 13-16, 2020 | Conference Website
- Poster: The HepQuant SHUNT Test of Global Liver Function and Physiology Identifies the Patients with Advanced Fibrosis or Compensated Cirrhosis Who are At-Risk for Hepatocellular Carcinoma
- Poster: Diagnostic Performance of The HepQuant Shunt Test in Prediction of Large Esophageal Varices in Well-Compensated Fibrosis or Cirrhosis Due to Chronic Hep C
Oral Presentation by Baylor – AASLD: The Liver Meeting Digital Experience | November 13-16, 2020
- Presentation: “Dual Cholate Test and Prediction of Decompensation, Liver Transplantation, Death and Hospitalization in Cirrhosis: A Prospective Study.
HepQuant CEO Greg Everson joined Proactive at the Biotech Showcase 2020 in San Francisco, Jan. 14th, 2020.
Greg Everson, MD, HepQuant’s Chief Executive Officer, presented at the NASH Summit 2019, in Boston. Dr. Everson was a key speaker during the Clinical Stream Segment entitled “Strategic Considerations for Phase 3 Clinical Trials.” Also attending on behalf of HepQuant were Randy Dietrich and Brad Everson.